Loading …
Loading Events

« All Events

Virtual Event Virtual Event
  • This event has passed.

NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound”

Virtual Event Virtual Event

May 26 @ 11:00 AM 12:00 PM

OVERVIEW
The National Cancer Institute (NCI), Technology Transfer Center (TTC) will host a webinar to highlight a cancer therapeutic technology for collaborative development and/or licensing. The webinar presented by the technology inventor, Dr. Joel Morris, will highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight. Registration is free.

PRESENTER
Joel Morris, Ph.D., Chief, Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute

DATE & TIME
Wednesday, May 26, 2021, 11:00am – Noon

WHY ATTEND
• Assess the prospect of potentially licensing this technology
• Interact with the inventor, ask questions and provide feedback.
• Learn how to partner with and license technology from the National Cancer Institute

WHO SHOULD ATTEND
• Business development professionals
• Drug development professionals
• Biotech/pharma/academia researchers
• Investors
• Entrepreneurs

TECHNOLOGY DESCRIPTION
• Potential therapeutic for various types of cancers – including colon cancer and leukemia
• Competitive in vivo efficacy study in several human tumor xenograft studies indicated low toxicity and high efficacy vs. gemcitabine.
• Produced complete tumor regression in colon cancer mouse models with a durable response beyond 150 days
• Complete tumor regression was observed in a leukemia mouse xenograft model
• Incorporating fluorine increases lipophilicity through steric and electronic effects

TECHNOLOGY COMPETITIVE ADVANTAGES
• Oral activity
• Increased lipophilicity blocks cancer cell metabolism and increases agent potency
• Increased selectivity and decreased toxicity compared to other aza-cytidines